<DOC>
	<DOCNO>NCT01471197</DOCNO>
	<brief_summary>The purpose trial determine whether Ipilimumab prolong survival compare Pemetrexed subject nonsquamous , non-small cell lung cancer .</brief_summary>
	<brief_title>Safety Efficacy Trial Ipilimumab Versus Pemetrexed Non-Squamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>For additional information , please contact BMS oncology clinical trial information service 8552160126 email MyCancerStudyConnect @ emergingmed.com . Please visit www.BMSStudyConnect.com information clinical trial participation . NonSquamous , NonSmall Cell Lung Cancer Recurrent/Stage IV Nonsmall cell lung cancer ( NSCLC ) Eastern Cooperative Oncology Group ( ECOG ) 0 1 Not progress 4 cycle platinumbased first line chemotherapy Brain Metastases ( unless stable ) Autoimmune Diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>